KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Current Assets: 2020-2025

Historic Current Assets for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $714.1 million.

  • Recursion Pharmaceuticals' Current Assets rose 50.60% to $714.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $714.1 million, marking a year-over-year increase of 50.60%. This contributed to the annual value of $714.3 million for FY2024, which is 63.02% up from last year.
  • Recursion Pharmaceuticals' Current Assets amounted to $714.1 million in Q3 2025, which was up 21.62% from $587.2 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Current Assets high stood at $714.3 million for Q4 2024, and its period low was $221.8 million during Q1 2021.
  • Its 3-year average for Current Assets is $519.2 million, with a median of $492.1 million in 2023.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Current Assets spiked by 179.26% in 2022, and later crashed by 30.18% in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Current Assets (Quarterly) stood at $534.7 million in 2021, then rose by 6.56% to $569.8 million in 2022, then declined by 23.11% to $438.1 million in 2023, then skyrocketed by 63.02% to $714.3 million in 2024, then skyrocketed by 50.60% to $714.1 million in 2025.
  • Its Current Assets stands at $714.1 million for Q3 2025, versus $587.2 million for Q2 2025 and $584.1 million for Q1 2025.